iRhythm Holdings designs and markets continuous heart rhythm monitoring systems that analyze data to predict cardiac arrest events for hospitals and ambulatory centers worldwide.
iRhythm represents a compelling growth story as it continues to expand its installed base of HeartWire® systems which generate recurring revenue through subscription-based software services. The company's unique value proposition of predicting cardiac events before they occur addresses an unmet clinical need in the $10B+ cardiovascular monitoring market. With a strong cash position of $236M and improving revenue trajectory, investors may view current valuation as attractive relative to future free cash flow potential.
Persistent net losses totaling nearly $45M in 2025 indicate that the company has not yet achieved sustainable profitability despite significant revenue growth. High operating expenses of $584.7M suggest inefficient cost management or aggressive expansion that may not be immediately accretive to shareholder value. The substantial retained earnings deficit of $803.4M combined with negative cash flow from operations relative to net income raises concerns about long-term financial viability without a clear path to breakeven.
iRhythm Holdings (IRTC) develops and manufactures Implantable Cardioverter Defibrillators (ICDs) that continuously monitor heart rhythm data to predict and prevent sudden cardiac death. The company serves hospitals, ambulatory surgery centers, and physicians globally with its proprietary HeartWire® monitoring system and associated software platforms. iRhythm's business model focuses on long-term patient monitoring rather than one-time device implantation, creating recurring revenue streams in the specialized cardiovascular care market.
Despite a $44.6M net loss in 2025, iRhythm demonstrated strong top-line growth with revenue climbing to $747.1M from $410.9M in 2022, reflecting successful market penetration and adoption of its monitoring technology. The company maintained robust operating cash flow of $80.9M which partially offset capital expenditures of $46.3M and investing outflows of $277.1M related to strategic acquisitions and development efforts. However, the widening deficit between operating expenses ($584.7M) and gross profit ($527.2M) suggests increasing margin compression that warrants scrutiny.
The cardiovascular device market is experiencing rapid growth driven by aging populations and increasing awareness of sudden cardiac death prevention strategies. Traditional implantable cardioverter defibrillators are being supplemented by advanced monitoring technologies that enable remote patient management and reduce healthcare costs. Consolidation among major players like Medtronic and Abbott creates both competitive pressure and opportunities for specialized innovators with differentiated technology platforms.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $410.9M | $492.7M | $591.8M | $747.1M |
| Cost of Revenue | $129.3M | $160.9M | $184.3M | $219.9M |
| Gross Profit | $281.6M | $331.8M | $407.5M | $527.2M |
| Operating Expenses | $395.4M | $457.0M | $523.0M | $584.7M |
| Operating Income | $-113.8M | $-125.2M | $-115.5M | $-57.4M |
| R&D | $46.6M | $60.2M | — | — |
| G&A | $322.2M | $385.6M | $418.6M | $492.6M |
| Stock-Based Comp | $57.7M | $77.2M | $76.0M | $88.3M |
| D&A | $13.4M | $16.3M | $20.7M | $20.7M |
| Other OpEx | $26.6M | $11.1M | $104.5M | $92.1M |
| Non-Operating Income | $-2.1M | $2.5M | $2.8M | $13.8M |
| Interest Expense | $4.1M | $3.6M | — | — |
| Interest Income | — | — | $21.9M | $21.5M |
| Pre-Tax Income | $-115.9M | $-122.7M | $-112.7M | $-43.6M |
| Income Tax | $269.0K | $750.0K | $565.0K | $953.0K |
| Continuing Ops | $-116.2M | $-123.4M | $-113.3M | $-44.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-116.2M | $-123.4M | $-113.3M | $-44.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-116.2M | $-123.4M | $-113.3M | $-44.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $288.8M | $230.8M | $645.8M | $702.8M |
| Cash & Equivalents | $78.8M | $36.2M | $419.6M | $236.0M |
| Marketable Securities | $134.3M | $97.6M | $116.0M | $347.8M |
| Accounts Receivable | $49.9M | $61.5M | $79.9M | $75.7M |
| Inventory | $15.2M | $14.0M | $14.0M | $21.6M |
| Prepaid Expenses | $10.6M | $21.6M | $16.3M | $21.7M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $159.4M | $202.3M | $285.6M | $317.3M |
| PP&E (Net) | $75.7M | $104.1M | $125.1M | $151.6M |
| Goodwill | $862.0K | $862.0K | $862.0K | $862.0K |
| Operating Leases | $60.7M | $49.3M | $47.6M | $41.8M |
| LT Investments | — | — | $61.9M | $69.9M |
| Other LT Assets | $22.3M | $48.0M | $46.7M | $49.2M |
| Total Assets | $448.2M | $433.1M | $931.4M | $1.02B |
| Current Liabilities | $89.1M | $107.4M | $110.9M | $151.9M |
| Accounts Payable | $7.5M | $5.5M | $7.2M | $2.3M |
| Current Leases | $13.0M | $15.2M | $15.9M | $16.7M |
| Deferred Revenue | $3.1M | $3.3M | $2.9M | $4.2M |
| Other Current Liab | $0 | $0 | $0 | $0 |
| Long-Term Liabilities | $119.3M | $115.7M | $729.6M | $715.4M |
| Long-Term Debt | $34.9M | $35.0M | — | — |
| LT Operating Leases | $83.1M | $79.7M | $74.6M | $65.0M |
| Other LT Liab | $1.3M | $1.0M | $655.0M | $650.4M |
| Total Liabilities | $208.4M | $223.0M | $840.5M | $867.3M |
| Shareholders' Equity | $239.8M | $210.1M | $90.9M | $152.7M |
| Retained Earnings | $-522.2M | $-645.6M | $-758.9M | $-803.4M |
| AOCI | $-396.0K | $-112.0K | $165.0K | $403.0K |
| Total L&E | $448.2M | $433.1M | $931.4M | $1.02B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-116.2M | $-123.4M | $-113.3M | $-44.6M |
| Non-Cash Adjustments | $7.7M | $-58.3M | $40.3M | $-16.4M |
| Working Capital Changes | $85.5M | $131.6M | $76.3M | $141.8M |
| Cash from Operations | $-23.0M | $-50.1M | $3.4M | $80.9M |
| Capital Expenditures | $29.8M | $40.4M | $33.9M | $46.3M |
| Cash from Investing | $-52.4M | $-1.2M | $-123.0M | $-277.1M |
| Debt Repayments | $21.4M | $0 | — | — |
| Share Buybacks | — | — | $25.0M | $0 |
| Cash from Financing | $26.7M | $8.8M | $511.4M | $12.6M |
| FX Effect | $0 | $-169.0K | $-6.0K | $1.0K |
| Net Change in Cash | $-48.7M | $-42.7M | $391.8M | $-183.6M |
| Beginning Cash | $127.6M | $78.8M | $36.2M | $428.0M |
| Ending Cash | $78.8M | $36.2M | $428.0M | $244.4M |
The company's revenue is primarily driven by its HeartWire® monitoring system which includes hardware implants, connected devices, and cloud-based software analytics. A secondary segment involves the sale of standalone external monitors and sensors for non-invasive rhythm detection in outpatient settings. Additional revenue streams include professional services, training programs for healthcare providers, and strategic partnerships with major device manufacturers.
Regulatory changes or stricter FDA requirements could impact the approval process for new device iterations or require costly redesigns. The highly competitive medical device market poses pricing pressure from established giants like Medtronic and Boston Scientific who have recently entered adjacent monitoring markets. Reimbursement policies by Medicare and private insurers may evolve to limit coverage for continuous monitoring services, affecting revenue per unit. Dependence on third-party component suppliers for manufacturing could disrupt production if supply chain constraints arise.
iRhythm's proprietary algorithms provide superior arrhythmia prediction accuracy compared to traditional ICDs by analyzing subtle pre-event electrical patterns. The company maintains a significant first-mover advantage as the only implantable continuous monitoring system approved by the FDA for predicting sudden cardiac death. Its scalable software platform allows for real-time remote patient management, reducing hospital readmissions and optimizing care delivery.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.